Diese Informationen sind zur Weitergabe an Patient:innen und Bürger:innen.
COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator
The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
COVAX is co-led by Gavi, the Coalition for Epide...mic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.
more
This article is part four in a series of explainers on vaccine development and distribution.
Part one focused on how vaccines work to protect our bodies from disease-carrying germs.
Part two focused on the ingredients in a vaccine and the three clinical trial phases.
Part three focused on the ste...ps from completing the clinical trial phases through to distribution.
This document outlines the different types of vaccines.
Available in English, French, Spanisch, Arabic, Chinese and Russian
more
The WHO Global Learning Laboratory (GLL) for Quality UHC links the experiences, expertise, and wisdom of people across the world on important issues relating to quality in the context of UHC. The GLL is a safe space to share knowledge, experiences and ideas; to challenge ideas and approaches; and to... spark new thinking for quality UHC
more
17 February 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines are safe, and getting v...accinated will help protect you against developing severe COVID-19 disease and dying from COVID-19. You may experience some mild side effects after getting vaccinated, which are signs that your body is building protection.
more
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are a critical tool in the battl...e against COVID-19, and getting vaccinated is one of the best ways to protect yourself and others from COVID-19.
more
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Countries around the world are rolling ou...t COVID-19 vaccines, and a key topic of interest is their safety. Vaccine safety is one of WHO’s highest priorities, and we’re working closely with national authorities to develop and implement standards to ensure that COVID-19 vaccines are safe and effective.
more
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
خطة النقاط الست للاستجابة والتعافي ووضع رؤية جديدة لعالم ما بعد الجائحة لكل طفل
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are supported by decades of medical research. ...They work by preparing the body's own immune system to recognise and defend against a specific disease. The volume of information available about vaccination can be overwhelming, so it’s important to talk through the topic.
Available in different languages
more
14 July 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines have proven to be safe, ...effective and life-saving. Like all vaccines, they do not fully protect everyone who is vaccinated, and we do not yet know how well they can prevent people from transmitting the virus to others. So as well as getting vaccinated, we must also continue with other measures to fight the pandemic.
Available in English, French, Spanish, Arabic, Chinese and Russian
more
Working Paper 589 July 2021T
Person-centred evidence based practice (EBP)- Clinical Pocket Reference - for students, nurses and other healthcare professionals
Tuberculosis (TB) is the leading cause of death from a single infectious agent even if is largely curable and
preventable. In 2019 an estimated 2.9 million of the 10 million people who fell ill with TB were not
diagnosed or reported to the World Health Organization1. The Politi...cal Declaration adopted by the United
Nations General Assembly in September 2018 commits, amongst others, to diagnosing and treating 40
million people with TB. In order to achieve these ambitious targets, there is an urgent need to deploy
strategies to improve diagnosis and initiation of care for people with TB. One of them is systematic
screening for TB disease, which is included in the End TB Strategy as a central component of its first pillar
to ensure early diagnosis for all with TB.
more
A Organização Mundial da Saúde (OMS), com apoio do Grupo Consultivo Estratégico de Especialistas em Imunização (Strategic Advisory Group of Experts on Immunization – SAGE) e do respectivo Grupo de Trabalho para Vacinas contra a COVID-19, está analisando novas evidências sobre o uso de vaci...nação heteróloga (conhecida também como vacinação mix and match). Na vacinação heteróloga, a segunda dose usa uma vacina diferente da que foi usada na primeira dose. Reforço heterólogo, por outro lado, refere-se à administração de uma vacina com plataforma tecnológica diferente da que foi usada para concluir o esquema primário de vacinação. Esta declaração provisória diz respeito apenas à vacinação heteróloga, e não ao reforço heterólogo.
more